Bedrijf laden
Just reported
Q3 2026 results
From Neurocrine Biosciences's results release of 2 november 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 1,12B
+41% y/y
+17% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$ 1,96
-3,9% y/y
+41% q/qGuided
—
No guide given
Operating income, GAAP
Actual
US$ 331,3M
+39% y/y
+119% q/qGuided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Neurocrine Biosciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company LimitedUS$ 34,4BA
ELANElanco Animal Health IncorporatedUS$ 13,4BA
KNSAKiniksa Pharmaceuticals International, plcUS$ 8,2BA+
LQDALiquidia CorporationUS$ 5,2BA
BHCBausch Health Companies Inc.US$ 3,1BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 okt 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 okt 2026CAGraded C, now A
Gebouwd uit de eigen deponeringen van Neurocrine Biosciences, Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
